Navigation Links
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Date:6/8/2009

Oral Presentation Details Dose Optimization of Pre-Clinical Otelixizumab Surrogate

NEW ORLEANS, June 8 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today presented results from a pre-clinical dose-optimization study conducted with a surrogate of its Phase 3 anti-CD3 monoclonal antibody, otelixizumab, at the 69th Scientific Sessions of the American Diabetes Association (ADA), which is continuing until June 9, 2009 in New Orleans, Louisiana.

The presentation (#297-OR), entitled "Dose Ranging Studies of an Anti-CD3 Antibody in NOD mice to Determine Minimum Effective Dose," was part of an Oral Session on Antigen-Specific and Non-Specific Regulation of Type 1 Diabetes. In the session, Dr. Devangi Mehta, Tolerx Senior Scientist, presented data demonstrating the effects of modified dosing regimens of the anti-CD3 monoclonal antibody in a commonly used non-obese diabetic (NOD) mouse model of autoimmune diabetes.

Tolerx researchers conducted dose-ranging studies to establish the minimum effective dose and to investigate pharmacodynamic (PD) parameters, including T-cell receptor (TCR) modulation, that correlate with efficacy in a preclinical model of diabetes. Evaluation of a dose of 8ug (0.0004mg/kg) of anti-CD3 antibody, a 30-fold reduction from previously investigated dosing regimens, induced up to 53% remission of diabetes, a response rate equivalent to those achieved with a 250ug (0.0125mg/kg) dosing regimen in other studies. This result demonstrates that lower doses of anti-CD3 monoclonal antibody, causing partial TCR modulation, are efficacious in this model, and that high doses resulting in full TCR modulation are not required to achieve similar rates of remission.

These data, combined with a rigorous Phase 2 clinical development program assessing more than 10 dosing regimens, have led
'/>"/>

SOURCE TolerRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
9. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
10. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas , 21. November 2014 ... was sich am Morgen des 14. Februar 2014 zugetragen ... jedoch wohl kaum vergessen. Video - ... dass ich dabei war, mein morgendliches Training zu machen", ... waren zu der Zeit begeisterte Anhänger der ...
(Date:11/21/2014)... Nov. 20, 2014   Wellcentive , the ... for healthcare organizations, announced today being named one ... Intel Innovation Award .  Sponsored by Intel, the ... its fourth year, recognizes companies developing leading-edge technology ... delivery processes. Wellcentive,s Mason ...
(Date:11/18/2014)... Nov. 18, 2014 Respiratory Motion and IMI ... medical device and services providers in Japan ... Respiratory Motion,s innovative respiratory depression monitor, the ExSpiron™. As ... are working together to connect the clinical community in ... history of bringing innovative medical devices and new technology ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
... Calif., Jan. 7 Hyperion,Therapeutics, Inc., a ... commercialization of hepatology and gastrointestinal,therapies that address ... needs, today announced that William R. Ringo ... and will serve as Chairman., (Logo: ...
... Jan. 7 Baxter International,Inc. (NYSE: BAX ... to develop recombinant Factor IX proteins to treat ... Factor IX therapy for,treatment of acute bleeding episodes ... IX therapy for prophylaxis of bleeding in,hemophilia B ...
Cached Medicine Technology:William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3
(Date:11/22/2014)... -- A clinical trial of hydroxyurea therapy for children ... early because the results show it is a safe ... the risk of stroke. The announcement about the ... the United States and Canada, was made this week ... (NHLBI). Researchers compared monthly blood transfusions with daily ...
(Date:11/22/2014)... Amy Norton HealthDay Reporter ... live in nursing homes may commonly deal with aggressive or ... The study of 10 centers in New York state found ... percent of residents were involved in some type of incident ... verbal clash, with someone yelling or cursing at another resident. ...
(Date:11/21/2014)... Nov. 20, 2014 (HealthDay News) -- The cost of ... percent in recent years, climbing to more than $322 ... increases in cost were seen with prediabetes care, which ... jumped 82 percent, the researchers added. In 2012, ... totaled more than $1,000 for every American. That total ...
(Date:11/21/2014)... PLYMOUTH and WOBURN, Mass. (PRWEB) November 21, 2014 ... will present two free workshops titled “Massachusetts Insurance Funding ... autism spectrum disorder (ASD) navigate their way through the ... must be covered under Massachusetts law and the most ... take place on Thursday, Dec. 4 from 6-8:00 p.m. ...
(Date:11/21/2014)... Recently, VogueQueen has released 18 ... promotion for the coming holiday season. People who register ... checking out. , The beach wedding dresses from VogueQueen.com ... the designs for the premium quality fabrics and dedicated ... good for the environment, they would bring more fun ...
Breaking Medicine News(10 mins):Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Beach Wedding Dresses on Sale for the Coming Holiday Season at VogueQueen.com 2
... diseases such as flu, measles, whooping cough and other ... from coming back. // ,Non-Hodgkin's lymphoma is ... comes back, even after chemotherapy and eventually most of ... their lymphoma. ,The vaccine is made from a ...
... worldwide epidemic with the highest incidence rate and a high ... cases and 299 deaths in a ,population of 6.7 million. ... of SARS in Hong Kong. It seems the air may ... health care professionals must take the potential for airborne spread ...
... 400,000 Americans undergo balloon angioplasty to clear blocked arteries. In ... drug may change the outcome of the procedure. ... can to avoid a second open-heart surgery. Eight years ago, ... earlier this year, Bailey had the same kind of chest ...
... milk, supplements, or other dairy products may actually make you ... mother always told you to drink your milk so you ... ,Participants in the study who consumed more calcium lost ... a breakdown of fat occurs. However, if the body consumes ...
... new findings in animals suggest a potential treatment to ... injuries . ,"Our approach is based on a ... stress protein response," say specialists . Researchers say the ... the "secondary" cell death that occurs in the hours ...
... reaction of blood vessels in the eyes may offer insight into ... brain react to high blood pressure, a major risk factor for ... also known as Atacand, improves blood flow in the eye, which ... is the lining of the vessel walls and plays a key ...
Cached Medicine News:Health News:New Findings Could Reduce The Extent Of Spinal Cord Injuries 2
... Induction Room., ,The Aestiva/5 Induction offers ... Aestiva/5 Induction has similar user interface as ... it easier for clinicians to use. The ... mixing, O2 failure alarm, N2O cutoff (with ...
... of performance and value., ,The Aestiva/5 ... of the Aestiva/5 anesthesia system (open architecture, ... Datex-Ohmedas newest anesthesia ventilation platform - the ... specifically engineered to allow for ventilation of ...
... The S/5 Aespire was developed using ... development close and continuous collaboration ... performance of the 7100 Ventilator with ... system solution designed for clinicians throughout ...
The Electronic bag and bottle ventilator especially designed for your circle system needs. Provides the anaesthetist with a wide range of economic anaesthesia solutions with the following outstanding...
Medicine Products: